NANO.PA PAR
Nanobiotix S.A.
1W: +43.6%
1M: +9.2%
3M: -10.1%
YTD: +60.2%
1Y: +86.1%
3Y: +460.6%
5Y: +285.3%
€30.24 ($33.63)
+2.02 (+7.16%)
Weekly Expected Move ±13.7%
€19
€22
€26
€29
€33
Credit Risk of going bust: higher than 64% of companies Debt: 6.6% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about 0.42 EUR (down 99%), Nanobiotix S.A. would be worth roughly what it owes.
Total debt $118.7M against a stock market value of $1.69B.
Distance to default 3.87 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $76.5M (short-term plus half of long-term), stock volatility 78.2%; Altman Z'' -0.10. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Total debt $118.7M against a stock market value of $1.69B.
Distance to default 3.87 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $76.5M (short-term plus half of long-term), stock volatility 78.2%; Altman Z'' -0.10. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap€1.5B ($1.7B)
52W Range13.1-47.66
Volume404,043
Avg Volume160,355
Beta0.59
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOLaurent Levy
Employees98
SectorHealthcare
IndustryBiotechnology
IPO Date2012-10-29
Websitenanobiotix.com
60 rue de Wattignies
Paris, IF 75012
FR
Paris, IF 75012
FR
33 1 40 26 04 70
About Nanobiotix S.A.
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.
Latest News
No recent news
Recent Insider Trades
No insider trades found